Grainger DW - Search Results

1

Nanoparticles in medicine: Current challenges facing inorganic nanoparticle toxicity assessments and standardizations.

Hofmann-Amtenbrink M, Grainger DW, Hofmann H. Hofmann-Amtenbrink M, et al. Among authors: grainger dw. Nanomedicine. 2015 Oct;11(7):1689-94. doi: 10.1016/j.nano.2015.05.005. Epub 2015 Jun 4. Nanomedicine. 2015. PMID: 26051651 Review.

2

In vivo human time-exposure study of orally dosed commercial silver nanoparticles.

Munger MA, Radwanski P, Hadlock GC, Stoddard G, Shaaban A, Falconer J, Grainger DW, Deering-Rice CE. Munger MA, et al. Among authors: grainger dw. Nanomedicine. 2014 Jan;10(1):1-9. doi: 10.1016/j.nano.2013.06.010. Epub 2013 Jun 28. Nanomedicine. 2014. PMID: 23811290 Free PMC article. Clinical Trial.

3

Delivery of large biopharmaceuticals from cardiovascular stents: a review.

Takahashi H, Letourneur D, Grainger DW. Takahashi H, et al. Among authors: grainger dw. Biomacromolecules. 2007 Nov;8(11):3281-93. doi: 10.1021/bm700540p. Epub 2007 Oct 12. Biomacromolecules. 2007. PMID: 17929968 Free PMC article. Review.

4

In vitro assessments of nanomaterial toxicity.

Jones CF, Grainger DW. Jones CF, et al. Among authors: grainger dw. Adv Drug Deliv Rev. 2009 Jun 21;61(6):438-56. doi: 10.1016/j.addr.2009.03.005. Epub 2009 Apr 19. Adv Drug Deliv Rev. 2009. PMID: 19383522 Free PMC article. Review.

5

A critical evaluation of in vitro cell culture models for high-throughput drug screening and toxicity.

Astashkina A, Mann B, Grainger DW. Astashkina A, et al. Among authors: grainger dw. Pharmacol Ther. 2012 Apr;134(1):82-106. doi: 10.1016/j.pharmthera.2012.01.001. Epub 2012 Jan 10. Pharmacol Ther. 2012. PMID: 22252140 Review.

6

Connecting drug delivery reality to smart materials design.

Grainger DW. Grainger DW. Int J Pharm. 2013 Sep 15;454(1):521-4. doi: 10.1016/j.ijpharm.2013.04.061. Epub 2013 Apr 24. Int J Pharm. 2013. PMID: 23624177

7

The 16th International Symposium on Recent Advances in Drug Delivery, February 3-6, 2013, Salt Lake City, UT, USA.

Bae YH, Grainger DW. Bae YH, et al. Among authors: grainger dw. J Control Release. 2013 Dec 10;172(2):393-4. doi: 10.1016/j.jconrel.2013.08.003. Epub 2013 Aug 8. J Control Release. 2013. PMID: 23933521 No abstract available.

8

Critical analysis of 3-D organoid in vitro cell culture models for high-throughput drug candidate toxicity assessments.

Astashkina A, Grainger DW. Astashkina A, et al. Among authors: grainger dw. Adv Drug Deliv Rev. 2014 Apr;69-70:1-18. doi: 10.1016/j.addr.2014.02.008. Epub 2014 Mar 5. Adv Drug Deliv Rev. 2014. PMID: 24613390 Review.

9

Nanoparticle toxicity assessment using an in vitro 3-D kidney organoid culture model.

Astashkina AI, Jones CF, Thiagarajan G, Kurtzeborn K, Ghandehari H, Brooks BD, Grainger DW. Astashkina AI, et al. Among authors: grainger dw. Biomaterials. 2014 Aug;35(24):6323-31. doi: 10.1016/j.biomaterials.2014.04.060. Epub 2014 May 10. Biomaterials. 2014. PMID: 24814424

10

Lyophilized liposome-based parenteral drug development: Reviewing complex product design strategies and current regulatory environments.

Wang Y, Grainger DW. Wang Y, et al. Among authors: grainger dw. Adv Drug Deliv Rev. 2019 Nov-Dec;151-152:56-71. doi: 10.1016/j.addr.2019.03.003. Epub 2019 Mar 18. Adv Drug Deliv Rev. 2019. PMID: 30898571 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

196 results

Search Page